Your browser doesn't support javascript.
loading
Chronic lymphocytic leukemia: a paradigm of innate immune cross-tolerance.
Jurado-Camino, Teresa; Córdoba, Raúl; Esteban-Burgos, Laura; Hernández-Jiménez, Enrique; Toledano, Victor; Hernandez-Rivas, Jose-Angel; Ruiz-Sainz, Elena; Cobo, Teresa; Siliceo, María; Perez de Diego, Rebeca; Belda, Cristobal; Cubillos-Zapata, Carolina; López-Collazo, Eduardo.
Afiliação
  • Jurado-Camino T; Tumor Immunology Laboratory, IdiPAZ, La Paz Hospital, Madrid 28046, Spain;
  • Córdoba R; Tumor Immunology Laboratory, IdiPAZ, La Paz Hospital, Madrid 28046, Spain; Hematology Department, University Hospital Infanta Sofía, San Sebastian de los Reyes, Madrid 28702, Spain;
  • Esteban-Burgos L; Tumor Immunology Laboratory, IdiPAZ, La Paz Hospital, Madrid 28046, Spain;
  • Hernández-Jiménez E; Tumor Immunology Laboratory, IdiPAZ, La Paz Hospital, Madrid 28046, Spain;
  • Toledano V; Tumor Immunology Laboratory, IdiPAZ, La Paz Hospital, Madrid 28046, Spain;
  • Hernandez-Rivas JA; Hematology Department, University Hospital Infanta Leonor, Madrid 28031, Spain;
  • Ruiz-Sainz E; Hematology Department, Hospital del Tajo, Aranjuez, Madrid 28300, Spain;
  • Cobo T; Hematology Department, Hospital del Sureste, Arganda del Rey, Madrid 28500, Spain;
  • Siliceo M; Tumor Immunology Laboratory, IdiPAZ, La Paz Hospital, Madrid 28046, Spain;
  • Perez de Diego R; Innate Immunity Group, IdiPAZ, La Paz Hospital, 28046 Madrid, Spain; Laboratory of Immunogenetics, IdiPAZ, La Paz Hospital, 28046 Madrid, Spain; and.
  • Belda C; HM Hospitales and National School of Health, Madrid, Spain.
  • Cubillos-Zapata C; Tumor Immunology Laboratory, IdiPAZ, La Paz Hospital, Madrid 28046, Spain; elopezc@salud.madrid.org carolina.cubillos@idipaz.es.
  • López-Collazo E; Tumor Immunology Laboratory, IdiPAZ, La Paz Hospital, Madrid 28046, Spain; Innate Immunity Group, IdiPAZ, La Paz Hospital, 28046 Madrid, Spain; elopezc@salud.madrid.org carolina.cubillos@idipaz.es.
J Immunol ; 194(2): 719-27, 2015 Jan 15.
Article em En | MEDLINE | ID: mdl-25505275
Infections are a significant cause of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL). The pathogenesis of infections is multifactorial and includes hypogammaglobulinemia, conventional therapy with alkylating drugs, and recently, purine analogs and mAb-associated T cells. Patients without these risk factors also suffer from infections, although the mechanism remains unknown. In a cohort of 70 patients with CLL, we demonstrated that their monocytes were locked into a refractory state and were unable to mount a classic inflammatory response to pathogens. In addition, they exhibited the primary features of endotoxin tolerance, including low cytokine production, high phagocytic activity, and impaired Ag presentation. The involvement of miR-146a in this phenomenon was suspected. We found miR-146a target genes, such as IRAK1 and TRAF6, were manifestly downregulated. Our study provides a new explanation for infections in patients with CLL and describes a cross-tolerance between endotoxins and tumors.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Monócitos / Linfócitos T / Leucemia Linfocítica Crônica de Células B / Tolerância Imunológica / Imunidade Inata Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Monócitos / Linfócitos T / Leucemia Linfocítica Crônica de Células B / Tolerância Imunológica / Imunidade Inata Idioma: En Ano de publicação: 2015 Tipo de documento: Article